Pakistan’s pharmaceutical sector just posted a major milestone—$457 million in exports for the fiscal year 2025 (FY25), the highest figure ever recorded in the country’s history. This marks a sharp 34% jump from the previous year, signaling strong momentum for one of the country’s quietly emerging industries.
Rapid Growth Over the Years
To put the growth into perspective: exports stood at $341 million in FY24, $328 million in FY23, and $269 million in FY22. That’s nearly a $200 million increase in just three years—an impressive trajectory for an industry that has historically flown under the radar compared to Pakistan’s dominant textile and agricultural exports.
What’s Driving the Boom?
One of the key drivers behind this surge has been a shift in policy. A report by Topline Securities attributes the export boom to the deregulation of pricing for non-essential drugs. This move has allowed pharmaceutical firms to invest more aggressively in product development and to tap into international markets with competitive offerings.
By removing the strict price controls on non-essential medicines, companies gained breathing room to innovate, enhance production capacity, and focus on global expansion rather than just local survival.
Future Outlook: More to Come
Topline Securities remains optimistic about the sector’s future, predicting that the upward trend is far from over. With greater regulatory flexibility and rising global demand for affordable quality pharmaceuticals, Pakistani firms are well-positioned to deepen their international footprint in the coming years.
If current momentum holds, the pharmaceutical sector could soon rival more established export industries in Pakistan—a development worth watching for investors and policymakers alike.
